Abstract P1-11-13: DE-REAL: ITALIAN MULTICENTER EXPERIENCE OF TRASTUZUMAB DERUXTECAN IN A REAL WORLD SETTING
Andrea Botticelli(Policlinico Umberto I), Alessandra Fabi(Agostino Gemelli University Polyclinic), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Simona Pisegna(Sapienza University of Rome), Simone Scagnoli(Sapienza University of Rome), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Robert Preißner(Humboldt-Universität zu Berlin), Michela Palleschi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Annarita Verrazzo(Scuola Superiore Meridionale), Giuliana D’Auria(Ospedale di Belcolle), Roberta Scafetta(Campus Bio Medico University Hospital), Antonella Palazzo(Agostino Gemelli University Polyclinic), Lidia Strigari(Azienda USL di Bologna), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Vittoria Barberi(Sapienza University of Rome), Daniele Santini(Policlinico Umberto I), Luigi Rossi(Sapienza University of Rome), Daniele Alesini, Rossana Berardi(Marche Polytechnic University), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Agnese Fabbri(Ospedale di Belcolle)
Cited by 1
Related Papers
ProTox 3.0: a webserver for the prediction of toxicity of chemicals
|Nucleic Acids Research|2024|1.2k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
SuperTarget and Matador: resources for exploring drug-target relationships
|Nucleic Acids Research|2007|665
SDM--a server for predicting effects of mutations on protein stability and malfunction
|Nucleic Acids Research|2011|578